header logo image


Page 144«..1020..143144145146..150160..»

A different kind of consult: pro-bono community health consulting by med students – Modern Healthcare

January 30th, 2022 1:47 am

Since 2015, groups of medical students at the Northwestern Feinberg School of Medicine in Chicago have been working diligently to answer a single question: How can we improve healthcare at the system level?

Medical students have and always will be expected to provide personalized, high-quality care to their patients. But amid all the studying, rotations, research and clinical volunteering, there is another area of professional growth and healthcare activism emerging that allows students to promote broader change across the healthcare system: community health consulting.

A group of students at Feinberg, now more than 50 in any given year, have been providing pro-bono strategy consulting services to community clinics and healthcare not-for-profits for more than six years as members of Second Opinions, a 501(c)(3) not-for-profit student organization founded by a trio of management consultants-turned-physicians. Second Opinions aims to promote system-level change in healthcare by pairing medical students with local healthcare organizations to support a variety of administrative and strategic initiatives.

Groups of four to five Second Opinions members work together on discrete projects for four months at a time, tackling problems in areas ranging from clinical workflow analysis to healthcare and not-for-profit economics. Current projects include helping one local community clinic improve its mammogram referral network and assisting a second clinic in the creation of an equitable sliding scale payment system for uninsured patients. While our projects are based on set timelines, we establish follow-up procedures in which we continue working with clients on emerging issues. This continuity-of-care approach is crucial across all levels of healthcare and is what drew many of us to medicine in the first place.

Download Modern Healthcares app to stay informed when industry news breaks.

Second Opinions shines brightest in its work to improve outcomes for underserved populations. Amid rising costs and legislative volatility in healthcare, Free and Charitable Clinics (FCCs) as well as Federally Qualified Health Centers (FQHCs) have led the way in providing accessible care to underinsured or uninsured Americans. To help them overcome their greatest obstacles, quantifying community impact and obtaining funding, our group recently created a reimbursement valuation tool to determine the monetary and quality-adjusted life years (QALY) values of services provided by free clinics as well as the value of appropriately averted emergency department visits.

The impact of our valuation tool started locally but soon gained national traction. First, we presented to the Illinois Association of Free and Charitable Clinics, a cluster of just over 40 FCCs. Soon, our team was presenting to board members of the National Association of Free and Charitable Clinics, an organization of over 1,400 FCCs. This information has important implications for how healthcare resources get distributed, and our work quantifying averted downstream costs and disease strengthened the case for investing in these providers.

System-level change does not have to occur on a national scale. The work can start by aiding a local women's health clinic in the transition from paper records to an efficient electronic health record system so that more underrepresented Chicagoans can be seen each day. It can be performing community health needs assessments for neighboring clinics that operate in Chicago's West and South Sides, or even helping our own institution expand the reach of its pediatrics mobile health program.

Through experiences like this, our medical student members learn how to effect change on system-level healthcare issues and leave empowered to help both individual patients and the systemequipped to care for the forest and the trees. The problems we face are complex and open-ended, and our members are challenged to find ways to measure system performance and enact change through policy, workflow improvements, and clinical protocols that benefit entire patient populations, particularly underserved ones. This is a tall order, but as medical students, our advantage is that we are always intimately observing from the inside with a fresh perspective and a passion for creative innovation.

Our members grew up in an era marked by healthcare disparities and inefficiencies. The dysfunction of our American healthcare system is broadcast to us throughout medical school. We are ready to innovate, and we believe physicians should always have a seat at the table when it comes to improving the healthcare system and operating the business of healthcare. Our members are eager to provide actionable recommendations and create solutions to problems that burden the same underrepresented patients we hope to care for in clinics and hospitals throughout our careers. We also realize we have much to learn. Our members remain humble, ready to begin each project by listening for as long as it takes to adequately understand the scope of the issue at hand. Most of all, our members are creativeunafraid to invent solutions where there is no precedent to guide them.

We encourage medical trainees across the country to join in our efforts to promote community health through strategy work. There is space for anyone who is dedicated to community health to help, and we are excited to support others with this important work. System-level change is difficult but powerful, so help where you are needed and get creative. And if you need a Second Opinions consult, you know who to page.

Drs. Cecil Qiu, Liz Nguyen and Benjamin Peipert contributed to this article. All graduated from Northwestern University Feinberg School of Medicine. Qiu is a resident at Johns Hopkins University School of Medicine, Nguyen is a resident at Stanford University School of Medicine, and Peipert is a resident at Duke University School of Medicine.

Read the rest here:
A different kind of consult: pro-bono community health consulting by med students - Modern Healthcare

Read More...

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

January 30th, 2022 1:45 am

Advanced four wholly owned and internally developed programs into clinical development

See the rest here:
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

Read More...

Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

January 30th, 2022 1:45 am

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place February 7 – 11, 2022 in San Diego, California. The presentations will include updated data from the Company’s ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1.

See the rest here:
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

Read More...

23andMe to Report FY2022 Third Quarter Financial Results

January 30th, 2022 1:45 am

SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February 10, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress.

Originally posted here:
23andMe to Report FY2022 Third Quarter Financial Results

Read More...

Vaccinex Announces $6.6 Million Private Placement

January 30th, 2022 1:45 am

Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022

Continued here:
Vaccinex Announces $6.6 Million Private Placement

Read More...

Applied Molecular Transport Announces Board Appointments

January 30th, 2022 1:45 am

John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair

More here:
Applied Molecular Transport Announces Board Appointments

Read More...

Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus

January 30th, 2022 1:45 am

MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Greek and Cypriot markets.

Read the original here:
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus

Read More...

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction…

January 30th, 2022 1:45 am

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “GC”).

More here:
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction...

Read More...

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

January 30th, 2022 1:45 am

The companies will continue with their exclusive agreements, including for commercialization of their current portfolio The companies will continue with their exclusive agreements, including for commercialization of their current portfolio

View post:
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

Read More...

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV…

January 30th, 2022 1:45 am

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner

See the article here:
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV...

Read More...

Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

January 30th, 2022 1:45 am

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Feb. 17, 2022 at 8:40 a.m. ET.

Originally posted here:
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

Read More...

Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3

January 30th, 2022 1:45 am

A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development

Continue reading here:
Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3

Read More...

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

January 30th, 2022 1:45 am

SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.

Read the original:
Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Read More...

Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

January 30th, 2022 1:45 am

-- HAV remained patent and host-cell remodeling was observed in non-human primate model ---- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery --

Go here to read the rest:
Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

Read More...

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in…

January 30th, 2022 1:45 am

CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that the U.S. Court of Appeals for the 11th Circuit has issued a mandate directing the District Court that heard Catalyst's claim against the FDA to enter summary judgment in favor of Catalyst in its lawsuit against the FDA, thereby vacating the FDA's approval of Ruzurgi® (Jacobus Pharmaceutical Company's amifampridine product).

Link:
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in...

Read More...

ObsEva Announces Corporate Updates

January 30th, 2022 1:45 am

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

View original post here:
ObsEva Announces Corporate Updates

Read More...

Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to…

January 30th, 2022 1:45 am

Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission

Follow this link:
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to...

Read More...

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30th, 2022 1:45 am

REDWOOD CITY, Calif., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to new employees.

Read more:
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More...

PAOG Publishes 2022 Strategic Update

January 30th, 2022 1:45 am

Sandusky, OH, Jan. 28, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today released a 2022 strategic update on the company’s CBD pharmaceutical and nutraceutical development strategy. The update is included in its entirety below:

Excerpt from:
PAOG Publishes 2022 Strategic Update

Read More...

Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units

January 30th, 2022 1:45 am

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Originally posted here:
Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units

Read More...

Page 144«..1020..143144145146..150160..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick